Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

NCT04139902 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage III
Melanoma Stage IV

Interventions

DRUG: Dostarlimab (TSR-042) (singly)
DRUG: Dostarlimab (TSR-042) and TSR-022 (combination)

Sponsor

Diwakar Davar

Collaborators

[object Object]